Replacement therapy with recombinant factor IX. A multicentre evaluation of current dosing practices in Italy

Blood Transfusion

Volumn 9, Issue 1, 2011, Pages 60-69

  Rocca, Alessandra ^a   Pizzinelli, Simona ^a   Oliovecchio, Emily ^a   Santagostino, Elena ^b   Rocino, Angiola ^c   Iorio, Alfonso ^a,d  

^a Haemophilia Centre of Perugia   (Italy)

^b Institute of Dermatological Sciences   (Italy)

^c San Giovanni Bosco Hospital   (Italy)

^d UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Factor IX; Haemophilia B; Recombinant FIX; Recovery

Indexed keywords

RECOMBINANT FACTOR IX; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL PRACTICE; DRUG DOSE REDUCTION; FEMALE; HEMOPHILIA B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; ITALY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRESCHOOL CHILD; SCHOOL CHILD; SUBSTITUTION THERAPY;

ADOLESCENT; ADULT; AGE FACTORS; AGED; FACTOR IX; FEMALE; FOLLOW-UP STUDIES; HEMOPHILIA B; HEPACIVIRUS; HEPATITIS C; HIV; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS;

EID: 78751521068     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2010.0011-10     Document Type: Article

References (21)

1. Soucie JM, Jackson D, Evatt B. Occurrence of hemophilia in the United States: The Hemophilia Surveillance System Project Invest. Am J Hematol 1998; 59: 288-94.
2. Iorio A, Oliovecchio E, Morfini M, et al. on behalf the Association of Italian Haemophilia Centres Directors. Report from the Italian National Haemophilia Database. Objectives, Methodology and Data Analysis as at December 2006. Haemophilia 2008; 14: 444-53.
3. National haemophilia registry data summary 2007. Available at: Http://www.aiceonline.it/emocard/2007/ Hemophilia%20B.pdf. Accessed on line on 15/01/ 2010.
4. Shapiro AD, White II GC, Kim HC, et al. Efficacy and safety of monoclonal antibody purified factor IX concentrate in haemophilia B patients undergoing surgical procedures. Haemophilia 1997; 3: 247-53.
5. Seitz R, Dodt J. Virus safety of prothrombin complex concentrates and factor IX concentrates. Thromb Res 1999; 95 (4 Suppl 1): S19-23.
6. Evatt BL, Farrugia A, Shapiro AD, Wilde JT. Haemophilia 2002: Emerging risks of treatment. Haemophilia 2002; 8: 221-9.
7. Hill FGH, Zaman A, Connor N, et al. Extent of exposure to and risk stratification of UK patients reated with plasma concentrates with contribution from a donor who developed vCJD. [abstract] J Thromb Haemost 2009, 7 (Suppl 2): OCMO- 033.
8. Kurachi k, Davie EW. Isolation and characterization of a cDNA coding for human factor IX. Proc Acad Sci USA: 1982; 79: 6461-4.
9. Choo GH, Gould KG, Rees DJ, Brownlee GC. Molecular cloning of the gene for human anti-haemophilic factor IX. Nature 1982; 299: 178-80.
10. Kaufman RJ, Wasley LC, Furie BC, et al. Expression, purification, and characterization of recombinant gammacarboxylated factor IX synthesized in Chinese hamster ovary cells. J Biol Chem 1986; 261: 9622-8.
11. Harrison S, Adamson S, Bonam D, et al. The manufacturing process for recombinant factor IX. Semin Hematol 1998; 35: 4-10.
12. Bond M, Jankowski M, Patel H, et al. Biochemical characterization of recombinant factor IX. Semin Hematol 1998; 35: 11-7.
13. White G, Shapiro A, Ragni M, et al. Clinical evaluation of recombinant factor IX. Semin Hematol 1998; 35 (2 Suppl 2): 33-8.
14. Roth DA, Kessler CM, Pasi KJ, et al. Recombinant Factor IX Study Group. Human recombinant factor IX: Safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood 2001; 98: 3600-6.
15. Bjorkman S, Shapiro AD, Berntorp E. Pharmacokinetics of recombinant factor IX in relation to age of the patient: Implications for dosing in prophylaxis. Haemophilia 2001; 7: 133-9.
16. Poon MC, Lillcrap D, Hensman C, et al. Recombinant factor IX recovery and inhibitor safety: A Canadian post-licensure surveillance study. Thromb Haemost 2002; 87: 431-5.
17. Ewenstein BM, Joist JH, Shapiro AD, et al. for the Mononine Comparison Study Group. Pharmacokinetics analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia Transfusion 2002; 42: 190-7.
18. Linee guida per la terapia sostitutiva dell'emofilia e dei difetti ereditari della coagulazione edite a cura di E. Santagostino approvate dai Direttori dei Centri Emofilia Italiani 2003. Available at: Http://www. aiceonline.it/documenti/LineeGuida/italia-Coagulopatie.pdf. Accessed on January 15th 2010.
19. Guidelines for the Management of Hemophilia World Federation of Hemophilia, 2005. Available at: Http://www.wfh.org/2/docs/Publications/ Diagnosis-and-Treatment/Guidelines-Mng-Hemophilia.pdf. Accessed on 15/01/2010.
20. Monahan PE, Liesner R, Sullivan ST, et al. Safety and efficacy of investigator-prescribed BeneFIX® prophylaxis in children less than 6 years of age with severe haemophilia B. Haemophilia 2010; 16: 460-8.
21. Martorell M, Altisent C, Parra R. Recovery of recombinant factor IX determined in clinical practice. Haemophilia 2009; 15: 840-2.